摘要
目的探讨氧磷酯酶1(paraoxonase-1,PON1)、丝氨酸肽酶4(HtrA serine peptidase 4,HtrA4)与拉贝洛尔治疗子痫前期合并代谢综合征效果的相关性。方法选择采用拉贝洛尔治疗的子痫前期患者114例,分为子痫前期不合并代谢综合征组(n=42)和子痫前期合并代谢综合征组(n=72),另选取正常妊娠妇女作为正常妊娠组(n=50)。比较3组治疗前后血清PON1、HtrA4水平。根据治疗效果将子痫前期合并代谢综合征组患者分为显效组、有效组和无效组,比较其治疗前后血清PON1、HtrA4水平,并进行相关性检验。结果治疗前,子痫前期合并代谢综合征组血清PON1水平低于子痫前期不合并代谢综合征组和正常妊娠组,血清HtrA4水平高于子痫前期不合并代谢综合征组和正常妊娠组(P<0.05)。子痫前期不合并代谢综合征组血清PON1水平低于正常妊娠组,血清HtrA4水平高于正常妊娠组(P<0.05)。治疗后,子痫前期合并代谢综合征及子痫前期不合并代谢综合征组血清PON1水平高于治疗前,血清HtrA4水平低于治疗前(P<0.05)。子痫前期合并代谢综合征组血清PON1水平低于子痫前期不合并代谢综合征组,血清HtrA4水平高于子痫前期不合并代谢综合征组(P<0.05)。治疗后,子痫前期合并代谢综合征组显效28例,有效36例,无效8例。治疗后,显效组、有效组、无效组血清PON1水平高于治疗前,血清HtrA4水平低于治疗前,显效组血清PON1水平高于有效组和无效组,血清HtrA4水平低于有效组和无效组,有效组血清PON1水平高于无效组,血清HtrA4水平低于无效组(P<0.05)。血清PON1水平与临床疗效呈正相关(P<0.05),血清HtrA4水平与临床疗效呈负相关(P<0.05)。结论血清PON1、HtrA4可能参与子痫前期合并代谢综合征的发生,与采用拉贝洛尔治疗的临床效果具有相关性,可能成为评估子痫前期合并代谢综合征治疗效果的新的生物学指标。
Objective To study the dependency between paraoxonase-1(PON1),HtrA serine peptidase 4(HtrA4)and the efficacy of Labe in the treatment of preeclampsia complicated with metabolic syndrome.Methods A totla of 114 patients of preeclampsia of gynecology and obstetrics were divided into preeclampsia without metabolic syndrome group(n=42)and preeclampsia with metabolic syndrome group(n=72).Normal pregnant women who were examined in our hospital at the same time were selected as normal pregnancy group(n=50).The clinical data,the levels of serum PON1 and HtrA4 before and after treatment of the three groups were compared.According to the therapeutic effect,the patients of preeclampsia with metabolic syndrome group were divided into three groups:obvious effective,effective and ineffective,the serum levels of PON1 and HtrA4 before and after treatment were compared,and the correlation test was carried out.Results Before the treatment,patients′serum PON1 level in preeclampsia with metabolic syndrome group was lower than that of preeclampsia without metabolic syndrome and normal pregnancy group,serum HtrA4 level higher than that of preeclampsia without metabolic syndrome group and normal pregnancy group(P<0.05).Patients′serum PON1 level in preeclampsia without metabolic syndrome group was lower than the normal pregnancy group,serum HtrA4 level higher than that of normal pregnancy group(P<0.05).After treatment,patients′serum PON1 level in preeclampsia with the metabolic syndrome group and preeclampsia without metabolic syndrome group was higher than the level before the treatment,serum HtrA4 level was lower than the level before treatment(P<0.05).The patients′serum PON1 level in the preeclampsia with metabolic syndrome group was lower than that of preeclampsia without metabolic syndrome group,serum HtrA4 level was higher than that of preeclampsia without metabolic syndrome group(P<0.05).After treatment,in the group of preeclampsia with metabolic syndrome,there were 28 cases with obvious effective curative effect,and 36 cases with effective curative effect and 8 cases with ineffective curative effect.After treatment,serum PON1 level in the obvious effective group,effective group and ineffective group was higher than that before treatment,serum HtrA4 level was lower than that before treatment,PON1 level in the effective group was higher than that in the effective group and ineffective group.Serum PON1 level in the effective group was higher than that in the ineffective group,and serum HtrA4 level was lower than that in the ineffective group(P<0.05).PON1 level was positively correlated with clinical curative efficacy,while HtrA4 level was negatively correlated with clinical efficacy(P<0.05).Conclusion Serum PON1 and HtrA4 are both involved in the occurrence of preeclampsia complicated with metabolic syndrome and are correlated with the clinical efficacy of Labe therapy.They may be the new biological index to evaluate the therapeutic effect of preeclampsia combined with metabolic syndrome.
作者
董淑晓
刘志虎
刘慧丽
石国素
郑莉霞
DONG Shu-xiao;LIU Zhi-hu;LIU Hui-li;SHI Guo-su;ZHENG Li-xia(Department of Obstetrics and Gynecology, Xingtai Third Hospital, Hebei Province, Xingtai 054000, China;Department of Obstetrics and Gynecology, Xingtai People′s Hospital, Hebei Province, Xingtai 054000, China)
出处
《河北医科大学学报》
CAS
2020年第9期1053-1057,共5页
Journal of Hebei Medical University
基金
邢台市科技计划项目(2017ZC082)。
